Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2004

01-07-2004 | Review Article

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

Authors: Lisa Bodei, Marta Cremonesi, Chiara Grana, Paola Rocca, Mirco Bartolomei, Marco Chinol, Giovanni Paganelli

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2004

Login to get access

Abstract

Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.
Literature
1.
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179(68):77–9
2.
Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. Mini review: the somatostatin receptor family. Life Sci 1995;57:1249–65PubMed
3.
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82
4.
Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28(7):836–46
5.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334(4):246–54
6.
Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653–68CrossRefPubMed
7.
Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, Di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77(2):402–8
8.
Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8(10):1041–4
9.
Bontenbal M, Foekens JA, Lamberts SW, et al. Feasibility, endocrine and anti-tumor effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer 1998;77:115–22PubMed
10.
O’Byrne KJ, Dobbs N, Propper DJ, et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999;79:1413–8CrossRefPubMed
11.
Macauley VM, Smith IE, Everard MJ, et al. Experimental and clinical studies with somatostatin analogue octreotide in small-cell lung cancer. Br J Cancer 1991;64:451–6PubMed
12.
Marschke RF Jr, Grill JP, Sloan JA, et al. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol 1999;22:15–7CrossRefPubMed
13.
Figg WD, Thibault A, Cooper MR, et al. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer 1995;75:2159–64PubMed
14.
Di Leo A, Bajetta E, Ferrari L, et al. A dose-finding study of lanreotide (a somatostatin analogue) in patients with colorectal carcinoma. Cancer 1996;78:35–42CrossRefPubMed
15.
Friess H, Buchler M, Beglnger C, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993;8:540–5PubMed
16.
Krenning EP, Kwekkeboom DJ, Bakker WH et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]-octreotide and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31
17.
Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]-octreotide: the Rotterdam experience. Semin Nucl Med 2002;32(2):110–22
18.
de Jong M, Bakker WH, Breeman WA et al. Pre-clinical comparison of [DTPA0, Tyr3]octreotide and [DOTA0, d-Phe1, Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998;75:406–11CrossRefPubMed
19.
Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, Maecke HR, Jermann E, Robertson C, Fiorenza M, Tosi G, Paganelli G. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 1999;26(8):877–86
20.
Cremonesi M, Bodei M, Rocca P, Stabin M, Maecke H, Paganelli G. Kidney protection during receptor-mediated radiotherapy with 90Y-[DOTA0, Tyr3]octreotide. Cancer Biother Radiopharm 2002;17(3):344
21.
Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S. 86Y-DOTA0)-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30(4):510–8
22.
National Council on Radiation Protection and Measurements. Misadministration of radioactive material in medicine—scientific background. Bethesda, MD 1991:27
23.
Bodei L, Chinol M, Cremonesi M, Paganelli G. Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl. Eur J Nucl Med 2002;29:1099–100CrossRef
24.
Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 2001;28(10):1447–9
25.
Behr TM, Behe M, Kluge G, Gotthardt M, Schipper ML, Gratz S, Arnold R, Becker W, Goldenberg DM. Nephrotoxicity vs anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging 2002;29(2):277–9
26.
Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28:1552–4PubMed
27.
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26(11):1439–47
28.
de Jong M, Krenning EP. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43(5):617–20
29.
Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30(2):207–16
30.
Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30(1):9–15
31.
Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, Veronese FM, Cremonesi M, Chiolerio F, Nardone E, Siccardi AG, Paganelli G. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998;78(2):189–97
32.
De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32(2):133–40
33.
Paganelli G, Zoboli S, Cremonesi, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Maecke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426–34PubMed
34.
Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide: the experience of the European Institute of Oncology group. Semin Nucl Med 2002;32(2):141–47
35.
Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43(5):610–6
36.
Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, Feelders RA, van Eijck CHJ, de Jong M, Srinivasan A, Erion JL, Krenning EP. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med 2003;30(3):417–22
37.
Kwekkeboom DJ, Bakker WH, Teunissen JJM, Kooij PPM, Krenning EP. Treatment with Lu-177-DOTA-Tyr3-Octreotate in patients with neuroendocrine tumors: interim results. Eur J Nucl Med Mol Imaging 2003;30(2):S231
38.
de Jong M, Kwekkeboom DJ, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med 2003;30:463–9
39.
de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP. [177Lu-DOTA(0), Tyr3]-octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92(5):628–33
40.
de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP. Tumour response after [90Y-DOTA0-Tyr3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841–6
41.
Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30(5):781–93
Metadata
Title
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
Authors
Lisa Bodei
Marta Cremonesi
Chiara Grana
Paola Rocca
Mirco Bartolomei
Marco Chinol
Giovanni Paganelli
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1571-4

Other articles of this Issue 7/2004

European Journal of Nuclear Medicine and Molecular Imaging 7/2004 Go to the issue

Original Article

Improving the quality of small animal brain pinhole SPECT imaging by Bayesian reconstruction

Controversies—For

Is BMIPP a sensitive marker for myocardial ischaemic stress?

News & Views

July 2004

Short Communication

99mTc-EDDA/HYNIC-TOC scintigraphy in the differential diagnosis of solitary pulmonary nodules

Short Communication

Technetium-99m-labelled red blood cell imaging in the diagnosis of hepatic haemangiomas: the role of SPECT/CT with a hybrid camera

Original Article

Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study